Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemtrada single-arm infusion reaction management study in RRMS
NL-OMON40753Phase 4Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alemtuzumab in multiple sclerosis (MS), sponsored by Sanofi. Primary endpoints: Distribution of infusion-associated reactions by toxicity grade, Number and percentage of infusion-associated reactions and 2 more. Started Nov 2014; status: active, not recruiting.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON40753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40753.